LCM
KROS icon

Lynx1 Capital Management’s Keros Therapeutics KROS Stock Holding History

Lynx1 Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-544,001
Closed -$8.61M – 18
2024
Q4 		$8.61M Buy
+544,001
New +$28.3M 3.23% 8

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Lynx1 Capital Management's KROS Position: Q1 2025 in Review

Lynx1 Capital Management sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 544,001 shares — an estimated $8.61M sold.

Lynx1 Capital Management first reported a position in KROS in Q4 2024 and held it in 1 quarter. The position peaked at $8.61M in Q4 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • Lynx1 Capital Management reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lynx1 Capital Management sold 544,001 Keros Therapeutics shares in Q1 2025, an estimated $8.61M.
  • Lynx1 Capital Management first reported a position in Keros Therapeutics in Q4 2024 and held it in 1 quarter.
  • Lynx1 Capital Management's Keros Therapeutics position peaked at $8.61M in Q4 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Lynx1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.